Planning clinical trial manufacturing: what changes when material becomes investigational product, how to choose a cdmo partner on slot availability and track record rather than on price, and the comparability work that makes a process change survivable

Planning the campaign

1. Transfer the process and the analytics together. A process transfers with its methods, and the methods have to be qualified at the receiving site. Laboratories routinely plan the process transfer and discover the analytical transfer afterwards, which is where several months go.
2. Budget an engineering batch that produces nothing saleable. Hold times, filter compatibility, mixing at the new vessel geometry and line speed all have to be re-established at scale. Programmes that plan straight into a clinical batch produce an investigation instead of material.
3. Choose the partner on slots and track record, not on quotation. Capacity in eighteen months is not capacity, and the format a site runs occasionally is the one that will cause problems. Ask what they run weekly, ask for a reference programme of your size, and confirm the slot with penalty terms that mean something.
4. Plan release, labelling and distribution into the timeline. Release testing, labelling in the languages and formats the protocol requires, and distribution to sites sit after the batch and routinely add weeks nobody scheduled. Map them before committing to a first patient date.
5. Treat any process change as a comparability exercise. A change of site, scale or a raw material has to be shown not to change the product, using the analytical package and, where the change is large, additional characterisation. Comparability planned in advance is a study; discovered late it is a delay.

Raw materials and the supply chain behind them

Single source raw materials, long lead items and anything animal derived are risks that surface late. Map them at the start, qualify a second source where you can, and order long lead items before the slot is confirmed rather than after.

Ask the partner which of your materials they already hold and qualify. A material already on their approved list saves weeks of incoming qualification.

Quality agreements and who decides what

A quality agreement names who does what: batch record review, deviation handling, investigation ownership, change control and release. Ambiguity in that document becomes a delay at the first deviation, and there is always a first deviation.

Agree the escalation path and name one decision maker on each side. Campaigns stall on questions nobody was empowered to answer far more often than on technical problems.

Stability and shelf life for the trial

The investigational product needs stability data supporting the shelf life used in the trial, and that study starts when the batch is made. Retesting and extending during the trial is normal and has to be planned.

Store retention samples and plan the storage of the clinical supply itself, including the temperature excursion procedure in transit. A shipment that arrived warm and was used anyway is a finding waiting to happen.

Common questions

What changes when material becomes investigational product?

It is manufactured under a quality system with a defined process, released against a specification by a responsible person, labelled according to the protocol and tracked to the site. The chemistry may be identical; everything around it is not.

How do I choose a cdmo partner?

On what they run routinely at your scale and format, their inspection and quality record, their real slot availability, and the people who would be assigned. Price separates quotations far less than those do.

How long does technology transfer take?

Longer than the manufacturing. Process and analytical transfer, an engineering batch and the documentation around them usually dominate the schedule, and the analytical half is the one most often forgotten at planning.

What is comparability and when do I need it?

Evidence that a product made after a change is the same as before, from the analytical package and sometimes extra characterisation. You need it whenever site, scale, process or a critical raw material changes, and it is far cheaper planned than discovered.

Browse by service class

• Compare Gene synthesis on advertised prices